CYTOKINES AND NEUROTROPHIC FACTORS IN THE SEVERITY ASSESSMENT OF CHILDREN AUTISM
Due to the steady increase in the number of children with autism and the high heterogeneity of clinical groups, the diagnosis of these disorders and their severity is an urgent problem in modern medicine. In the course of the work, 126 children from 3 to 13 years old with typical neurodevelopment and with severe and mild autism spectrum disorders (ASD) were examined. Disease severity was determined according to the Childhood Autism Rating Scale (CARS). The levels of pro-/anti-inflammatory cytokines and neurotrophic factors (nerve growth factor beta and brain-derived neurotrophic factor) in blood plasma were assessed by enzyme immunoassay. Associations between indicators in each group of patients were assessed using the Spearman test and visualized as a heatmap of correlations. Statistical data processing was carried out in the R software. Significantly high levels of IL-4 in blood plasma and a decrease in the number of significant correlations within/between systems were revealed in children with mild autism compared with children with typical neurodevelopment. Such data can probably reflect the theory that some children with ASD are characterized by slow brain development, as a variant of the evolutionary norm. On the contrary, in children with severe ASD, high systemic levels of IL-6 and IFNg are shown against the background of low values of IL-10, IL-1β, TNFα and NGFβ, supported by the almost complete absence of intra/ and intersystem interactions. This may act as an indicator of maladaptation of the immune and nervous systems in severe autism, which contributes to the pathogenesis of the disease. Thus, a set of indicators: high levels of key pro-inflammatory cytokines - IL-6 and IFNg, low levels of IL-10, NGFβ and disintegration of the cytokine and nervous systems in the periphery can be proposed as an approach to indicate the severity of the condition in children with ASD.
About the authorsFilippova Yu.Yu.
Xu N., Li X., Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators Inflamm. 2015; 2015: 531518.
Skogstrand K., Hagen C.M., Borbye-Lorenzen N., Christiansen M., Bybjerg-Grauholm J., Bækvad-Hansen M. et al. Reduced neonatal brain-derived neurotrophic factor is associated with autism spectrum disorders. Transl. Psychiatry. 2019; 9(1): 252.
Ohja K., Gozal E., Fahnestock M., Cai L., Cai J., Freedman J.H. et al. Neuroimmunologic and Neurotrophic Interactions in Autism Spectrum Disorders: Relationship to Neuroinflammation. Neuromolecular Med. 2018; 20(2): 161-73.
Toscano C.V.A., Barros L., Lima A.B., Nunes T., Carvalho H.M., Gaspar J.M. Neuroinflammation in autism spectrum disorders: Exercise as a “pharmacological” tool. Neurosci. Biobehav. Rev. 2021; 129: 63-74.
Matta S.M., Hill-Yardin E.L., Crack P.J. The influence of neuroinflammation in Autism Spectrum Disorder. Brain Behav. Immun. 2019; 79: 75-90.
Dipasquale V., Cutrupi M.C., Colavita L., Manti S., Cuppari C., Salpietro C. Neuroinflammation in Autism Spectrum Disorders: Role of High Mobility Group Box 1 Protein. Int. J. Mol. Cell Med. 2017; 6(3): 148-55.
Yirmiya R. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011; 25(2): 181-213.
Minnone G., De Benedetti F., Bracci-Laudiero L. NGF and Its Receptors in the Regulation of Inflammatory Response. Int. J. Mol. Sci. 2017; 18(5): 1028.
Calabrese F., Rossetti A.C., Racagni G., et al. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front. Cell Neurosci. 2014; 22: 430.
Galic M.A., Riazi K., Pittman Q.J. Cytokines and brain excitability. Front. Neuroendocrinol. 2012; 33: 116–25.
Park H., Poo M.M. Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 2013; 14(1): 7-23.
Skaper S.D. Nerve growth factor: a neuroimmune crosstalk mediator for all seasons. Immunology. 2017; 151(1): 1-15.
Jin Y., Sun L.H., Yang W., Cui R.J., Xu S.B. The Role of BDNF in the Neuroimmune Axis Regulation of Mood Disorders. Front. Neurol. 2019; 10: 515.
Pancheva R., Georgieva M. Autism spectrum disorders: neurotrophins enter the dance. Biomedical Reviews. 2014; 25: 93-9.
Mostafa G.A., Meguid N.A., Shehab A.A.S., Elsaeid A., Maher M. Plasma levels of nerve growth factor in Egyptian autistic children: Relation to hyperserotonemia and autoimmunity. J. Neuroimmunol. 2021; 358: 577638.
Goines P.E., Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. Neurotoxicol. Teratol. 2013; 36: 67-81.
Baron-Cohen,S. Editorial perspective: neurodiversity – a revolutionary concept for autism and psychiatry. J. Child Psychol. Psychiatry. 2017; 58(6): 744-7.
Crespi B. Developmental heterochrony and the evolution of autistic perception, cognition and behavior. BMC Med. 2013; 11: 119.
Gomez-Fernandez A., de la Torre-Aguilar M.J., Gil-Campos M., Flores-Rojas K., Cruz-Rico M.D., Martin-Borreguero P. et al. Children With Autism Spectrum Disorder With Regression Exhibit a Different Profile in Plasma Cytokines and Adhesion Molecules Compared to Children Without Such Regression. Front. Pediatr. 2018; 6: 264.
Rodrigues D.H., Rocha N.P., Sousa L.F., Barbosa I.G., Kummer A., Teixeira A.L. Circulating levels of neurotrophic factors in autism spectrum disorders. Neuro. Endocrinol. Lett. 2014; 35(5): 380-4.
Aloe L., Rocco M.L., Bianchi P., Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J. Transl. Med. 2012; 10: 239.
Prencipe G., Minnone G., Strippoli R., De Pasquale L., Petrini S., Caiello I. et al. Nerve growth factor downregulates inflammatory response in human monocytes through TrkA. J. Immunol. 2014; 192(7): 3345-54.
Для цитирования: Филиппова Ю.Ю., Девятова Е.В., Алексеева А.С., Бурмистрова А.Л. Цитокины и нейротрофические факторы в оценке степени тяжести аутизма у детей. Клиническая лабораторная диагностика. 2022; 67(11): 647-651. https://doi.org/10.51620/0869-2084-2022-67-11-647-651
For citation: Filippova Yu.Yu., Devyatova E.V., Alekseeva A.S., Burmistrova A.L. Cytokines and neurotrophic factors in the severity assessment of children autism. Klinicheskaya Laboratornaya Diagnostika (Russian Clinical Laboratory Diagnostics). 2022; 67(11): 647-651 (in Russ.). https://doi.org/10.51620/0869-2084-2022-67-11-647-651
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.